Abstract 152P
Background
The detection of copy number alterations (CNAs) is an informative molecular layer in the diagnosis, prognosis, and treatment of lung adenocarcinoma. Traditional tissue biopsies are invasive and often impractical. This study investigates the use of nanopore sequencing on circulating cell-free DNA (cfDNA) as a non-invasive, PCR-free method to detect CNAs in lung adenocarcinoma patients.
Methods
Native cfDNA samples from lung adenocarcinoma patients were analysed using low coverage nanopore sequencing (∼ 1- 3 X). Bioinformatics analysis identified CNAs, which were compared to known CNA patterns in tissue samples. Additionally, tumor fractions were estimated to correlate with tumor stage and aggressiveness.
Results
Nanopore sequencing of cfDNA revealed clinically significant and informative CNAs, including amplifications of 1q (MDM4), chromosome 7 (EGFR) as well as deletion of 8p. These alterations closely mirrored the classic CNA patterns observed in lung adenocarcinoma tissue samples, especially in cfDNA samples derived from patients with progressive cancers (i.e. stage 3-4). The analysis also provided tumor fraction estimates, which correlated with tumor stage and aggressiveness.
Conclusions
This study demonstrates that nanopore sequencing of cfDNA can accurately detect CNAs and estimate tumor fractions, offering a non-invasive alternative to tissue biopsies. This approach holds significant potential for real-time cancer monitoring, prognosis prediction, targeted therapy, and precise cancer subtyping. Estimating tumor fractions is also useful for predicting cancer progression and determining future sequencing coverage and planning.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Renovaro Cube.
Disclosure
K. Roohollahi, E. Post, D. Makarawung, F. van Asch: Financial Interests, Institutional, Stocks/Shares: Renovaro Cube. D. Vessies, J. van den Berg: Financial Interests, Personal, Stocks/Shares: Renovaro Cube.
Resources from the same session
71P - When neighbors play a role: The importance of interacting proteins in the tumorigenic effect of cancer driver genes
Presenter: Margarida Carrolo
Session: Cocktail & Poster Display session
Resources:
Abstract
72P - SNCG promotes the malignant progression of hepatocellular carcinoma by activation EGFR signaling and recycling
Presenter: Yue Chen
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - TROP2 amplification is highly present in dedifferentiated liposarcoma: Data from the Cancer Genome Atlas (TCGA) in soft tissue sarcoma
Presenter: Sarah Orlando
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - The influence of genetic phenotype on prognosis of osteosarcoma
Presenter: Nasirov Kamalovich
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Immune engager compounds screening using CRC patient-derived organoids
Presenter: Claudia Maria A. Pinna
Session: Cocktail & Poster Display session
Resources:
Abstract
77P - Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer
Presenter: Juan Jiménez-Vacas
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Exploring ecDNA heterogeneity and evolution in non-small cell lung cancer
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Targeting galectin-9 in BRCA mutant breast cancer
Presenter: Chun Yan So
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Suppression of glioblastoma progression by FDA-approved central nervous system-accumulating drugs via autophagy modulation and ER stress-induced apoptosis
Presenter: Smita Dey
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Evaluating the effect of lenvatinib-resistance in hepatocellular carcinoma cells and in lenvatinib-resistant patient-derived PBMCs
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract